In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...
The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...
Beta Bionics, Inc. (BBNX) is planning to raise $112 million in an initial public offering on Thursday, January 30th, IPO Scoop reports. The company will be issuing 7,500,000 shares at $14.00-$16.00 ...
President Donald Trump’s early action on health care reversed some of his predecessor’s policies, but former President Joe ...
Insulin delivery device maker Beta Bionics said on Wednesday it was targeting a valuation of as much as $615.9 million in its initial public offering in the United States, underscoring a gradual ...
The final proposed model would have had Medicare pay less for drugs that receive accelerated approvals from the Food and Drug ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.
Copyright 2025 The Associated Press. All Rights Reserved. President Joe Biden speaks about prescription drug costs at the National Institutes of Health in Bethesda ...
The Biden administration announced ... out-of-pocket costs at $35 for covered insulin products. Beginning Jan. 1, enrollees in Medicare's Part D drug plans had their out-of-pocket expenses for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback